Gilead announced results from phase 3 trial of Remdesivir in patients with moderate COVID-19
On Jun. 1, 2020, Gilead Sciences announced topline results from the Phase 3 SIMPLE trial in hospitalized patients…
Roche initiated phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
On May 28, 2020, Roche announced it had initiated of a global phase III, randomised, double-blind, multicentre study…
Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against COVID-19 pneumonia
On May 16, 2020, a single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six…
RedHill Biopharma received FDA approval for COVID-19 clinical study with opaganib in the U.S.
On May 8, 2020, RedHill Biopharma announced the U.S. Food and Drug Administration (FDA) had approved its Investigational…
Mateon announced filing of IND with FDA to evaluate antisense drug candidate OT-101 in COVID-19 patients
On Apr. 27, 2020, Mateon Therapeutics announced announced it has submitted an Investigational New Drug application to the…
BioAegis demonstrated Gelsolin therapy can quell the cytokine storm and promote tissue repair
On Apr. 27, 2020, BioAegis Therapeutics announced it had published gene expression data in animal studies where recombinant…
OpGen subsidiary Curetis GmbH and Karolinska Institutet collaborated in study of bacterial Co-infections in COVID-19 pneumonia patients
On Apr. 21, 2020, OpGen announced the start of an investigator initiated collaboration with Karolinska Institutet, Sweden, to…
RedHill Biopharma announced agreement with NIAID to evaluate RHB-107 against COVID-19
On Apr. 20, 2020, RedHill Biopharma announced an agreement with the National Institute of Allergy and Infectious Diseases…
Alexion announced plans to initiate phase 3 study of ULTOMIRISﾮ (ravulizumab-cwvz) in hospitalized patients with severe COVID-19
On Apr. 20, 2020, Alexion announced plans to initiate a global Phase 3 study to investigate ULTOMIRISﾮ (ravulizumab-cwvz)…
FDA approved initiation of Humanigen’s phase III study of lenzilumab in COVID-19 patients
On Apr. 15, 2020, Humanigen announced that U.S. Food and Drug Administration (FDA) had given permission to commence…
Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
Mateon achieved milestone in development of OT-101, a phase 3 clinical drug candidate, against COVID-19
On Apr. 6, 2020, Mateon Therapeutics announced an update on its rapid antiviral response program targeting coronaviruses, initially…
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program
On Apr. 2, 2020, Novartis announced plans to initiate a phase III clinical trial in collaboration with Incyte…
BioAegis accelerated multiple clinical trial submissions for severe COVID-19 pneumonia patients
On Apr. 2, 2020, BioAegis Therapeutics announced that it was preparing to evaluate plasma gelsolin replacement in severe…
Humanigen partnered with CTI for planned phase III study for lenzilumab for coronavirus treatment
On Mar. 30, 2020, Humanigen announced that the company had submitted an initial protocol synopsis to the FDA…
Mateon reported positive results for multiple COVID-19 drug candidates
On Mar. 25, 2020, Mateon Therapeutics announced an update on its rapid antiviral response program targeting coronaviruses, initially…
City of Hope researchers developing COVID-19 vaccine
On Mar. 24, 2020, City of Hope announced that it had employed its vast expertise using the immune…
New study expanded understanding of influenza-associated complications
On Mar. 20, 2020, a study was published in JAMA that expands the understanding of influenza-associated complications. Influenza…
Roche initiated phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
On Mar. 19, 2020, Roche is working with the FDA to initiate a randomised, double-blind, placebo-controlled Phase III…
Genentech Initiated Phase III Clinical Trial Of Actemra In Hospitalized Patients With Severe COVID-19 Pneumonia
On Mar. 18, 2020, Genentech announced that the company was working with the U.S. Food & Drug Administration…
Israel weighed “compassionate use” of Pluristem therapy for COVID-19
On Mar. 17, 2020, Israel’s Health Ministry announced that it had approved a request by Pluristem Therapeutics to…
MediciNova announced plans to develop MN-166 (ibudilast) for severe pneumonia and ARDS
On Mar. 9, 2020, MediciNova announced that it planned to initiate development of MN-166 (ibudilast) for severe pneumonia…
COVID-19 coronavirus spike holds infectivity details
On Feb. 24, 2020, researchers reported that the spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia…
NIH officials discussed novel coronavirus that recently emerged in China
On Jan. 23, 2020, the new cluster of viral pneumonia cases originating in Wuhan, China, marked the third…
Novel coronavirus identified as cause of a cluster of pneumonia cases in Wuhan, China
On Jan. 9, 2020, the World Health Organization announced that a novel coronavirus had been identified as the…
New pneumococcal vaccine from Serum Institute of India achieved WHO prequalification
On Dec. 19, 2019, the WHO announced that PNEUMOSIL, a vaccine against a leading cause of deadly childhood…
Biotechnology | CDC | FDA | Life Science News | NIH | Non-Profit Research | Pharmaceutical | Vaccine
CDC published updated ACIP recommendations for use of PCV13 and PPSV23 pneumococcal vaccines for adults age 65 and older
On Nov. 22, 2019, the Centers for Disease Control and Prevention”s (CDC) Advisory Committee on Immunization Practices (ACIP)…
PAHO/WHO announced measles elimination in the Americas
On Sept. 27, 2016, the Region of the Americas was the first in the world to have eliminated…
FDA extended the age indication for PCV13 (Prevnar 13) to include adults age 18 through 49 years
On Jul. 12, 2016, Pfizer announced that Prevnar 13ﾮ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received FDA…
Biotechnology | CDC | FDA | Life Science News | NIH | Non-Profit Research | Pharmaceutical | Vaccine
CDC published updated ACIP recommendations regarding the intervals between PCV13 and PPSV23 vaccines
On Sept. 4, 2015, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices…